A new way to unravel the genes behind salt tolerance in crop plants

New materials for high-voltage supercapacitors

Self-Powered Sensor Helps Track Firefighters in Burning Buildings

Flexible sensors for monitoring babies in the NICU with precision and without wires

An interdisciplinary Northwestern University team has developed a pair of soft, flexible wireless body sensors that replace the tangle of wire-based sensors that currently monitor babies in hospitals’ neonatal intensive care units (NICU) and pose a barrier to parent-baby cuddling and physical bonding. The team recently completed a collection of first human studies on premature babies at Prentice Women’s Hospital and the Ann & Robert H. Lurie Children’s Hospital in Chicago and concluded that the wireless infant sensors provided data as precise and accurate as that from traditional monitoring systems. The wireless patches also are gentler on a newborn’s fragile skin and allow for more skin-to-skin contact with the parent.

15 days ago

EPAD - innovative medical device that brings everyday neuromonitoring in an easy to use format

SafeOp Surgical, Inc. was formed in 2011 to fill the need for focused cost effective neuro-monitoring and particularly for detection of peripheral nerve damage caused by nerve compression, ischemia or stretching during surgery. This injury may occur due to patient positioning or surgical wound traction. While many surgeries can benefit from neuromonitoring for detection of both peripheral and central nervous system injuries, it is typically restricted to surgeries of the head, neck, brain, and spine. SafeOp's goal was to develop a simple, low cost and easy to use portable system that would allow caregivers to extend the benefits neuromonitoring outside these procedures and easily detect abnormalities in nervous system function including those due to positioning. The result of years of development is the innovative EPAD device.

15 days ago

Spider silk could be used as robotic muscle

A novel technology that might lead to new kinds of artificial muscles or robotic actuators has been developed by the researchers at MIT. The resilient fibers, the team discovered, respond very strongly to changes in humidity. Above a certain level of relative humidity in the air, they suddenly contract and twist, exerting enough force to potentially be competitive with other materials being explored as actuators - devices that move to perform some activity such as controlling a valve. Researchers recently discovered a property of spider silk called super contraction, in which the slender fibers can suddenly shrink in response to changes in moisture. The new finding is that not only do the threads contract, they also twist at the same time, providing a strong torsional force.

15 days ago

A new way to greatly enhance extraction of water from gases

Mission Bio: transforming single-Cell DNA analysis

IDEAYA Biosciences: an oncology-focused precision medicine company

Esophageal thermal regulating intervention that achieves and maintains precise body temperature

Fewer than 1% of the patients who could benefit from targeted temperature management actually receive this potentially life-saving intervention. Attune Medical is changing that. The company is committed to advancing temperature management therapy in all clinical contexts and is focused on three crucial pillars: clinical needs, the state of science, and most importantly, patient safety. The ensoETM gives healthcare providers easy access to a patient’s core and allows precise temperature control, whether warming or cooling, through the esophagus when clinically indicated. It’s the only approved device on the market that uses the esophageal environment for full-body temperature control.

18 days ago

Breakthrough therapies for patients with severe and rare disorders

Rallybio is a privately-held development-stage biotechnology company incorporated in January 2018.  Its ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development.  The company will identify and accelerate the development of highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. It is estimated that rare diseases affect an estimated 25 to 30 million Americans and the European Organization for Rare Diseases (EURORDIS) estimates that six to eight percent of the population of the European Union is affected by one. A rare disease, also sometimes called an orphan disease, is generally considered to be a disease that affects fewer than 200,000 people in the United States at any given time. While EURORDIS estimates that there are as many as 5,000 to 7,000 distinct rare diseases, the National Human Genome Institute claims that there are more than 6,800 rare diseases.

18 days ago

Arvinas: targeted protein degradation for the treatment of various diseases

Arvinas is a biopharmaceutical spinoff focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. Its proprietary PROTACTM protein degraders, or Proteolysis-Targeting Chimera, work by inducing the cell’s own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Building on groundbreaking research at Yale University by Craig Crews, Ph.D., Arvinas’ Founder and Chief Scientific Advisor, Arvinas has developed a broad technology platform focused on high-value targets, with the potential to deliver safer, more potent treatment than small molecule inhibitors, and to address up to 80% of proteins that evade inhibition and are currently undruggable. The Company’s therapeutic development is initially focused on developing degraders for high-value targets in cancer (lat. Carcinoma), including the androgen and estrogen receptors.

18 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.



100% Free of Cost For Scientists:

  • One hour of USA/EU attorney consulting
  • 24/7 support of 24 in-house professionals
  • 10 GB space for every scientist (own German Servers)
  • Syndicates with the leading professionals
  • 2,000 000 views of top spinoff are guaranteed
  • The largest DB of professional Investors - over 30.000

100% Free of Cost For Investors:

  • Investment information on 8,000+ spinoffs per year
  • All documents in one place (after NDA)
  • Testimonials from Key Opinion Leaders
  • AI-SDB hides irrelevant spinoffs - saved time up to 90% 
  • One-Click-Reports (OCRs) in own tailored design (PDF)

100% Free of Cost For Universities:

  • Professional Science Spinoff University Report (PDF)
  • No Links to Spinoff.com - Ready to Print and Share
  • Professional dossiers on over 27Tsd VC/PE/FO/ML
  • Professional dossiers on over 3Tsd MNC